No Data
No Data
Rigel to Present at the 2024 Cantor Global Healthcare Conference
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
Express News | Rigel Announces First Patient Enrolled in Phase 1B/2 Triplet Therapy Trial of Rezlidhia® (Olutasidenib) in Midh1 Aml
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA (Olutasidenib) in MIDH1 AML
Express News | Kissei Pharmaceutical Co Ltd - Licensing Agreement for "Olutasidenib", an Acute Myeloid Leukemia Drug
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
H.C. Wainwright analyst Joseph Pantginis maintains $Rigel Pharmaceuticals(RIGL.US)$ with a buy rating, and maintains the target price at $57.According to TipRanks data, the analyst has a success